Remove category
Remove 2015 Remove Compliance Remove Fraud Remove Medicare
article thumbnail

Compliance lessons from recent fraud cases

Health Care Performance

A New York ENT physician was convicted of filing false claims with Medicare and Medicaid. The physician submitted claims totaling about $585,000 to Medicare and Medicaid and was paid roughly $191,000. Mole billing fraud scheme totals $4.1 million in fraudulent payments between 2015 and 2021. That is how you collect $4.1

Fraud 52
article thumbnail

How HHS-OIG, Regulators Enforce Vendor Compliance

Provider Trust

What the HHS-OIG says about vendor compliance. If the answer is yes, then the best mechanism for limiting CMP liability is to screen all persons that perform under that contract or that are in that job category. In January 2015, the OIG settled for $96,259 with a Minnesota Pharmacist, Joseph C. Case Study: S. Martino-Fleming v.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What is a HIPAA Violation?

HIPAA Journal

To best answer the question what is a HIPAA violation, it is necessary to explain what HIPAA is, who it applies to, and what constitutes a violation; for although most people believe they know what a HIPAA compliance violation is, evidence suggests otherwise. HIPAA Violation Categories. There are four HIPAA violation categories.

HIPAA 135
article thumbnail

OIG Issues Information Blocking Penalties Final Rule: Health IT Developers and Health Information Exchanges/Networks Have a Million Reasons to Care

Health Law RX

Those subject to the CMP Final Rule should consider prioritizing their compliance efforts because the OIG will begin enforcing the Rule on September 1, 2023. 2] The information blocking provisions of the Cures Act apply to three categories of actors: healthcare providers, Developers, and HIN/HIEs.

Fraud 52
article thumbnail

Logical Contradiction Doctrine:  Buckman for Textualists

Drug & Device Law

470 (1996), was decided – removing express preemption as a defense for manufacturers of §510(k) products So defendants moved on fraud on the FDA under an implied preemption theory and won. Mensing , 564 U.S. Mensing , 564 U.S. Lohr , 518 U.S. Davidowitz , 312 U.S. Davidowitz , 312 U.S.

FDA 72